Tesamorelin
TH9507 · Egrifta · Egrifta SV · Egrifta WR · trans-3-hexenoyl-GHRH(1-44)
Last updated
At a glance
Tesamorelin is a peptide that stimulates the body’s release of growth hormone. It is best known for reducing visceral fat—the fat surrounding internal organs—in adults with HIV-associated lipodystrophy. Fitness and biohacking communities also explore it for abdominal fat and body composition. Dosage and preparation depend on the formulation; the guide below compares clinical references, community experiences and timing practices.
Dosage references · Cycle length · Peptide calculator · Compare suppliers
Buying options
Available at Real Peptides (US) — 20% off auto-applied
Affiliate link — we may earn a commission at no cost to you.
- Fat Loss
- 7/10
- Recovery
- 5/10
- Muscle Growth
- 2/10
- Cognition
- 2/10
- Endurance
- 1/10
- Strength
- 0/10
Overview
What tesamorelin research shows#
Tesamorelin is a growth hormone-releasing hormone analogue. Its clearest human evidence concerns excess visceral fat in adults with HIV-associated lipodystrophy.
In a 26-week trial of 412 patients, visceral fat measured by CT fell 15.2% in the tesamorelin group and increased 5.0% with placebo. Those measurements concern internal abdominal fat, rather than a guaranteed change in body weight or visible abdominal definition.
A separate 12-month study in people with HIV and fatty liver assessed liver fat. Its population matters when interpreting the results: it does not establish the same outcome for every person researching tesamorelin for bodybuilding or general fat loss.
For another compound comparison, see HGH Fragment 176-191 vs Tesamorelin.
How Tesamorelin works
GHRH, growth hormone and IGF-1#
Tesamorelin acts through the growth hormone-releasing hormone pathway. The phase 3 pooled analysis recorded increased IGF-1 alongside reductions in visceral fat in adults with HIV and excess abdominal fat. A mechanism explains why a compound is studied; the trial determines what was observed in a particular population.
What the preclinical work adds#
Ferdinandi and colleagues studied TH9507 in laboratory and animal models, including its resistance to degradation and effects on GH and IGF-1. Animal elimination times should not be presented as a universal human half-life.
What mechanism alone cannot establish#
The cited studies do not establish an optimal bodybuilding stack, a universal fasting window, or predictable weekly fat loss for a healthy individual. Those questions require their own evidence.
Protocol
Tesamorelin dosage references#
These are formulation-specific label instructions and study regimens, provided for comparison. They are not interchangeable instructions for research vials.
| Reference | Reported daily amount | Context |
|---|---|---|
| Egrifta SV label | 1.4 mg | Prescription formulation; follow its own preparation instructions |
| Egrifta WR label | 1.28 mg | Different prescription formulation and preparation; not substitutable for SV |
| Falutz 2007 trial | 2 mg | Historical study regimen in adults with HIV-associated abdominal fat accumulation |
The amount printed on a vial is the amount in the container, not automatically one administration. A generic beginner/intermediate/advanced ladder would obscure these distinctions.
Research-vial measurement#
The peptide calculator converts amounts and concentrations using the inputs you enter. It does not choose a dose, establish a preparation's stability, or validate a human protocol. Use the exact product information for a laboratory calculation.
Available at Real Peptides (US) — 20% off auto-applied
Affiliate link — we may earn a commission at no cost to you.
Cycle length & outcomes
Tesamorelin cycle length: study duration and community practice#
The 2007 trial assessed 26 weeks of treatment. The pooled phase 3 analysis included a further 26-week extension, and the HIV/NAFLD trial assessed its primary liver-fat outcome at 12 months.
These durations explain the published evidence. They do not establish a single bodybuilding cycle, a routine break length, or a universal point at which results plateau. A short personal experiment also cannot be compared directly with those trial populations and endpoints.
Morning or evening? Community reports#
In a February 2024 timing discussion, one commenter preferred mornings after reporting worse sleep with evening use; another reported better sleep with evening use. The first also described combining tesamorelin with ipamorelin.
These are personal accounts with differing experiences and co-use, not a controlled morning-versus-evening comparison. They are useful context for the timing question, but cannot establish that a particular schedule improves results. Discussion reviewed October 14, 2026.
Risks & mistakes
Known clinical considerations#
The prescribing information describes fluid retention, joint discomfort, injection-site reactions, glucose intolerance and increased IGF-1. Glucose and IGF-1 monitoring belong to clinician-directed care; a fixed internet bloodwork schedule cannot account for individual circumstances.
Active malignancy, disruption of the hypothalamic-pituitary axis, pregnancy and known hypersensitivity are among the labeled contraindications. Seek immediate medical help for a suspected serious allergic reaction. The full label contains additional precautions and interactions.
The 2012 responder analysis found different metabolic changes among trial responders and nonresponders. Average study findings do not guarantee an individual's response or make research-vial products equivalent to the studied formulation.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.15 | ×1.22 | ×1.25 | |
| synergistic | ×1.12 | ×1.23 | ×1.10 | |
| synergistic | ×1.10 | ×1.08 | ×1.22 | |
| synergistic | ×1.15 | ×1.22 | ×1.07 | |
| synergistic | ×1.15 | ×1.22 | ×1.05 | |
| synergistic | ×1.15 | ×1.20 | ×1.10 | |
| synergistic | ×1.08 | ×1.20 | ×1.12 | |
| synergistic | ×1.05 | ×1.18 | ×1.10 | |
| synergistic | ×1.13 | ×1.18 | ×1.14 | |
| synergistic | ×1.10 | ×1.18 | ×1.10 | |
| additive | ×1.00 | ×1.08 | ×1.00 |
Featured in stacks1 curated protocol include Tesamorelin
FAQ — Tesamorelin
Where to buy Tesamorelin
Real Peptides
Our pick20% off — auto-applied at checkout
- Buy Tesamorelin · 20% offTesamorelin 10mg
Swiss Chems
10% off — auto-applied at checkout
- Buy Tesamorelin · 10% offTesamorelin, 2mg - SwissChems-Buy Best Quality Peptides, SARMS Online
NextGenPeps
10% off — use code at checkout
- Buy Tesamorelin · 10% offTesamorelin
You'll also need
- Bacteriostatic waterReal PeptidesBuy · 20% off
- Bacteriostatic waterNextGenPepsBuy · 10% offUse code at checkout
- Bacteriostatic waterSwiss ChemsBuy · 10% off
- Sterile waterSwiss ChemsBuy · 10% off
- Spray bottle 10 mlSwiss ChemsBuy · 10% off
- Acetic acid 0.6% solution 10 mlSwiss ChemsBuy · 10% off
Research & citations
5 studies cited on this page.
Conclusion
Tesamorelin has human evidence for specific clinical populations, and its formulation matters when reading dosage information. Use the linked studies to understand the results and the community section to understand reported experiences.
Review the dosage references, use the calculator, or compare research suppliers.
Similar compounds
Comparisons
Disclosures
Affiliate links — we may earn a commission at no cost to you.